Tumor Biology

, Volume 37, Issue 6, pp 8075–8082 | Cite as

Circulating miR-205: a promising biomarker for the detection and prognosis evaluation of bladder cancer

  • Zhenqiang Fang
  • Wei Dai
  • Xiangwei Wang
  • Wei Chen
  • Chongxin Shen
  • Gang Ye
  • Longkun Li
Research Article

Abstract

MicroRNA (miRNA) expression profile analysis indicated that miR-205 was upregulated in bladder cancer tissue compared to healthy tissue. The aim of this study is to analyze value of circulating miR-205 for the detection and prognosis evaluation of bladder cancer (BC). Eighty-nine patients with BC and 56 healthy controls (HC) were enrolled in the study. miR-205 expression was determined using TaqMan quantitative real-time polymerase chain reaction assay and further correlated with patients’ clinicopathological parameters and follow-up data. The results indicated that plasma miR-205 was upregulated in BC compared with HC (P < 0.001) and in muscle invasive BC (MIBC) compared to nonmuscle invasive BC (NMIBC) (P = 0.016). miR-205 yielded an area under the receiver-operating characteristic curve of 0.950 with 76.4 % sensitivity and 96.4 % specificity in discriminating BC from HC, and 0.668 with 57.1 % sensitivity and 77.0 % specificity in distinguishing MIBC from NMIBC. Plasma miR-205 expression was significantly associated with tumor stage (P < 0.001) and pathological grade (P = 0.048). The results indicated that BC patients with high miR-205 expression experienced shorter disease-free survival and disease-specific survival (P = 0.022 and P = 0.026; P = 0.027 and P = 0.034; respectively), which was not proven by multivariate Cox regression analysis (multi-Cox) (P = 0.0765 and P = 0.279, respectively). Log-rank test showed that NMIBC patients with high miR-205 expression experienced shorter cancer-free survival (P = 0.044). Log-rank test and univariate and multivariate Cox regression analyses did not indicate that high miR-205 expression in NMIBC patients was associated with cancer-specific survival (P = 0.079, P = 0.089, and P = 0.201, respectively). In conclusion, miR-205 may be a promising biomarker for the detection and prognosis evaluation of BC.

Keywords

Humans miR-205 Bladder cancer Biomarker Survival analysis 

Notes

Acknowledgments

This study was supported by the National Natural Science Foundation of China (No. 81200500) and Natural Science Foundation Project of CQ CSTC (No. CSTC, 2009BB5154).

Conflict of interest

None

References

  1. 1.
    American Cancer Society. Cancer facts and figures 2012. Atlanta: American Cancer Society; 2012.Google Scholar
  2. 2.
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59(6):997–1008.CrossRefPubMedGoogle Scholar
  3. 3.
    Ratert N, Meyer HA, Jung M, Lioudmer P, Mollenkopf HJ, Wagner I, et al. miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn. 2013;15(5):695–705.CrossRefPubMedGoogle Scholar
  4. 4.
    Sexton WJ, Wiegand LR, Correa JJ, Politis C, Dickinson SI, Kang LC. Bladder cancer: a review of non-muscle invasive disease. Cancer Control. 2010;17(4):256–68.PubMedGoogle Scholar
  5. 5.
    Liu J, Zhu H, Yang X, Ge Y, Zhang C, Qin Q, et al. Micro-RNA-21 is a novel promising target in cancer radiation therapy. Tumor Biol. 2014;35(5):3975–9.CrossRefGoogle Scholar
  6. 6.
    Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101(9):2999–3004.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007;25(5):387–92.CrossRefPubMedGoogle Scholar
  8. 8.
    Dip N, Reis ST, Timoszczuk LS, Viana NI, Piantino CB, Morais DR, et al. Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile. J Urol. 2012;188(5):1951–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Silva Neto B, Lavoie AK, et al. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol. 2011;29(6):794–801.CrossRefPubMedGoogle Scholar
  10. 10.
    Cao Y, Yu SL, Wang Y, Guo GY, Ding Q, An RH. MicroRNA-dependent regulation of PTEN after arsenic trioxide treatment in bladder cancer cell line T24. Tumor Biol. 2011;32(1):179–88.CrossRefGoogle Scholar
  11. 11.
    Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhjin BW, Comperat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639–53.CrossRefPubMedGoogle Scholar
  12. 12.
    Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2012;36(8):449–60.Google Scholar
  13. 13.
    Wang S, Li Q, Wang K, Dai Y, Yang J, Xue S, et al. Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. Clin Transl Oncol. 2013;15(10):849–54.CrossRefPubMedGoogle Scholar
  14. 14.
    Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005;11(7):2625–36.CrossRefPubMedGoogle Scholar
  15. 15.
    Neely LA, Rieger-Christ KM, Neto BS, Eroshkin A, Garver J, Patel S, et al. A microRNA expression ratio defining the invasive phenotype in bladder tumors. Urol Oncol. 2010;28(1):39–48.CrossRefPubMedGoogle Scholar
  16. 16.
    Nam EJ, Lee M, Yim GW, Kim JH, Kim S, Kim SW, et al. MicroRNA profiling of a CD133(+) spheroid-forming subpopulation of the OVCAR3 human ovarian cancer cell line. BMC Med Genomics. 2012;5(1):18.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Cao P, Zhou L, Zhang J, Zheng F, Wang H, Ma D, et al. Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck. 2013;35(5):720–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Karaayvaz M, Zhang C, Liang S, Shroyer KR, Ju J. Prognostic significance of miR-205 in endometrial cancer. PLoS One. 2012;7(4):e35158.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Qin AY, Zhang XW, Liu L, Yu JP, Li H, Wang SZ, et al. MiR-205 in cancer: an angel or a devil? Eur J Cell Biol. 2013;92(2):54–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Tran MN, Choi W, Wszolek MF, Navai N, Lee IL, Nitti G, et al. The p63 protein isoform DeltaNp63alpha inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem. 2013;288(5):3275–88.CrossRefPubMedGoogle Scholar
  21. 21.
    Wiklund ED, Bramsen JB, Hulf T, Dyrskiot L, Ramanathan R, Hansen TB, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer. 2011;128(6):1327–34.CrossRefPubMedGoogle Scholar
  22. 22.
    Liang HH, Wei PL, Hung CS, Wu CT, Wang W, Huang MT, et al. MicroRNA-200a/b influence the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells. Tumor Biol. 2013;34(5):3209–18.CrossRefGoogle Scholar
  23. 23.
    Habuchi T, Marberger M, Droller MJ, Hemstreet GP, Grossman HB, Schalken JA, et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology. 2005;66(1):64–74.CrossRefPubMedGoogle Scholar
  24. 24.
    Matsushima K, Isomoto H, Yamaguchi N, Inoue N, Machida H, Nakayama T, et al. MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med. 2011;9(1):30.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Tran N, McLean T, Zhang X, Zhao CJ, Thomson JM, O’Brien C, et al. MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun. 2007;358(1):12–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Ribeiro IP, Marques F, Caramelo F, Ferrao J, Prazeres H, Juliao MJ, et al. Genetic imbalamces detected by multiplex ligation-dependent probe amplification in a cohort of patients with oral squamous cell carcinoma-the first step towards clinical personalized medicine. Tumor Biol. 2014;35(5):4687–95.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Zhenqiang Fang
    • 1
  • Wei Dai
    • 2
  • Xiangwei Wang
    • 1
  • Wei Chen
    • 1
  • Chongxin Shen
    • 1
  • Gang Ye
    • 1
  • Longkun Li
    • 1
  1. 1.Department of Urology, Center of NephrologyThe Second Affiliated Hospital of the Third Military Medical UniversityChongqingChina
  2. 2.Chongqing Petroleum HospitalChongqingChina

Personalised recommendations